Therapeutic Response

HER2-negative and PR positive status confers therapeutic sensitivity to Sacituzumab govitecan in patients with Invasive Breast Carcinoma.

Statements

Source and description
Trodelvy (sacituzumab govitecan) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Trodelvy (sacituzumab govitecan) [product information]. EMA. The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).